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Lab, North Chicago. Ill). HGV antibody was measured by enzymc- 
linked immunosorbent assay (ELISA) using recombinant E2 protein 
(Hoehringer Manheim). HCV antibodies were detected with an 
automated detection system (ELISA, Abbott Lab, North Chicago, 
111). HCV-RNA was measured by reverse transcriptase-polymerase 
chain reaction (KT-PCR, Cobas-Amplicor, Roche). Cenotyping 
was undertaken with a reverse hybridization test of the aniplification 
obtained by RT-PCR (Innogenetics, Belgium). Serologic markers of 
HBV investigated were HBsAg and HBcAb (Abbott Lab, North 
Chicago, Ill). 
Results: The mean age was 27 years (range 18-47) and 24 (48%) 
were intravenous drug users (IVDUs). Of the 50 women, 34 (68%) 
were HCV Ah potitives and 24 (48%) were HGV Ab positives. 21 of 
the 24 with HGV Ab were also HCV Ab positive. HGV viremia was 
present in 20% of the total samples, and HCV viremia was found in 
48%. The HCV genotypes most frequently observed were la  (25%) 
and 3 (25%). Five prostitutes (10%) were co-infected with HGV and 
HCV, all of them IVDUs. Only two were HBsAg carriers, and 27 
(%%I) had positive HBcAb. 
)p5381 Acute non-A-E hepatitis in Turkey and the role 
of l T V  and other viruses 
E Tabak’, A. Mert’, S. Ergin’, R. Uztiirk’, S. Tiirkoglu2, S. 
Badur’, H. Sentiirk’, Y. Aktuglu. ’Department of Clinical Baderiology 
arid Ir!fr.itiotrs Disemcs, Cerralipasa Medical Faculty, ‘Department of 
Ciiriiral Microbiolojy arid Microbioloxy, Israanbul Medical Faculty, Istatzbrrl 
I Iniversity, Istanbul, 7irrkey 
Objectives: To determine the causes of acute viral hepatitis (AVH) 
in Turkey and to assess the relative iniportance of TTV (transfusion- 
transmitted virus) in patients with AVH who are seronegative for 
hepatitis A-E, CMV, EBV and parvovirus B19 Infections. 
Methods: We selected patients with AVH who had acute disease 
during January 1996 to October 1998. Their mean age was 24 (range: 
11-74) and 71 were male. Of the 109 cases of AVH, 88% were due 
to one of the four recognized hepatitis viruses (A-D). Proportions of 
HAV, HUV, HCV and HDV were 38.4%, 49.5’%, 2.7% and 0.9%, 
respectively. The sera of 8 patients of 13 seronegative patients were 
tested by ELISA for IgM to EBV, CMV, parvovirus 819  and HEV; 
by PCR for HBV-DNA, HCV-RNA and HEV-RNA; and by nested 
PCR for TTV-DNA. All patients were negative for TTV and other 
viruses. Thirteen patients without diagnosis denied alcohol intake, 
the use of hepatotoxic drugs and blood transfusion. 
Results: TTV is not an etiologic agent of non-A-E hepatitis in 
Turkey 
Conclusions: Approximately 12% of the AVH cases have un- 
known etiology in Turkey. One or more additional agents may be 
responsible for AVH. Therefore, efforts must be directed to search 
for new hepatitis viruseq. 
HIV-virology and treatment 
(p5391 Do time since HIV infection, basal CD4 count 
and viral load influence response to HAART? 
J.M. Guardiola, P. Doniingo, J. Ris, M. Gurgui, J. Cadafalch, M.A. 
Sambeat, J. Lbpez-Contreras, J. Barrio, G.Vizquez. Infernal 
Medicine, Hospital Sant Pau, Barcelom, Spain 
We studied the influence of time since HIV infection, bacal CD4 
count and viral load on the immunologic and virologic response of 
an unselected cohort of patients with HAART after 18 months of 
treatment. We included those patients who had started antiretroviral 
treatment with AZT (or D4T) plus 3TC plus IDV between 
November 1996 and March 1997. All patients were PI naive. Patients 
were divided into groups according to basal CD4 count (<SO, 
51-100, 101-200, 201-500 and >500/iilnl’) and viral load 
(>1 000 000, 500 000-999 999, 100 000-499 999, 50 000-99 999, 
10 000-49 999 copies/inL) and time since HIV infection 
(> 10.9-10.7-8,s-6,3-4, <3 years). 140 patients were analyzed. 
Average age was 38.4k9.7years (21-74). 103 (74%) were men. 
Mean time since HIV infection was 6.224.0 years (1-13). B a d  viral 
load and CD4 count were 495 61021 359 309 copies/niL 
(0-11 000 000) and 212t184/min3 (3-1093). Mean viral load 
decrease after treatment and CU4 count impi-oveiiicnt were 
469 968k  1 380 749 copies/niL and 172~164/iiini”. When coinpar- 
ing different basal CD4 count groups, no statistically significant 
differences were found ( ~ ~ 0 . 2 )  for the virologic response but they 
were for immunologic response (p=0.0009). When comparing basal 
viral load groups, statistically significant differeiicer were found for 
the virologic response (p=O.0001) but not for the iiiiinunologic 
response ( p 0 . 9 ) .  Considering time from HlV infection, no sigiiifi- 
cant differences were found for either virologic or immunologic 
response. 
Conclusions: In our series, basal CD4 count influenced 
immunologic response, and basal viral load influenced virologic 
response. Time since infection did not affect either parameter 
(p5401 Eighteen-month follow-up of a population of 
HIV-infected patients in HAART: daily clinical 
praxis 
M. Guardiola, E Montero, M. Barcelo, T? l)oiningo, J. Ris, M. 
Gurgui, M.A. Sambeat, J. L6pez-Contreras, G. Vizquez. Internal 
Medicine, Hosprtal Smt pau, Barcelona, S p i n  
We studied the immunologic, virologic and clmical response of an 
unselected cohort ofpatients with HAART after 18 months of treat- 
ment. Patients were included provided that they had begun triple 
antirrtroviral treatment with AZT (or D4T) plus 3TC plus Il’IV 
between November 1996 and March 1997. All patients were PI 
naive. 140 of 160 (87.5%) patients were analyzed. Average age was 
38.459.7yrars (21-74). 103 (74%) were men. Mean tiine since HIV 
infection was 6.2k4.0 years. Mean duration of prior antiretroviral 
treatment was 32.3f9.1 months (0-34). 25 (18%) were naive. Basal 
viral load and CD4 count were 495 610+-1 359 309 copies/mL 
(0-1 1 000 000) and 212f 184/1iini’ (3-1093). Mean viral load 
decrease after treatment and CD4 count improvement were 
469 968k1 380 749 copies/mL and 172-t1h4/nim3. 88 (63%) 
patients had undetectable viral load. 41 (29%) needed a change in 
treatment after an average o f 8 2 4  months (1-17). IDV was changed 
in 65% of cases. 21% needed a change in the whole treatnir‘nt. 
Treatment was changed due to secondary effects (SE) in 62% and due 
to therapeutic failure in 38%. Main SEs were: nephrolithiasis in 9.2% 
lipodystrophy in 2.1%. toxic hepatitis in 1.4%. paresthesias in 2.1% 
anemia in 2.8% and gastrointestinal intolerance in 11.4%. 16 (1 1.4%) 
patients needed hospital admission: 2 due to herpe5 zoster, 2 due to 
non-Hodgkin lyniphoma, 7 due to nephrohthiasis, 2 due to diarrhea 
and 3 due to lipodystrophy. N o  patient suffered opportunistic infec- 
tions or died during the follow-up. Good conipliance was observed 
in 81% of cases. 
Conclusions: (1) Good immunologic and virologic outconm 
were observed after 18-month follow-up in patients with HAART. 
(2) Overall clinical status was maintained during the period. 
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HAART and CD4 T-cell count variation 
F. Maggiolo, P. Bottura, G. Pravettoni, G. Migliorino, F. Suter. 
Division of Inffctious Diseases, General Hospital, Busto Arsizio, Italy 
Objectives: To analyze the effect of HAART on CD4 T-cell counts 
in HIV-infected patients. 
Methods: Observational community-based study on an ongoing 
cohort treated with a triple drug combination containing one 
protease inhibitor. 
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Results: 292 HIV patients, who received HAART and had a 
follow-up up to 64 weeks, were analyzed. Their median basal HIV- 
RNA level was 67440 copies/mL (SDk233 161) with a median CD4 
T-cell count of 2002179 cells/mcl. CD4 T-cell counts varied over 
time in relation to the response of patients to HAART as measured 
by HIV-RNA serum levels ( h i t  of detection 200 copies/mL). Four 
categories of patients were identified subjects with HIV-RNA serum 
levels steadily undetectable (l), subjects rebounding after an initial 
maximal response (2) and subjects with persistently positive HIV- 
RNA at low (3) or high (above 15 000 copies/mL) level (4). Only 
patients with sustained high viral loads showed CD4 T-cell counts 
significantly lower than the other groups. 
Conclusions: The immunologic effect of HAART is maximal in 
steadily undetectable subjects, but a partial reduction of HIV-RNA 
levels below 10 000 copies/mL induces a similar sustained and 
durable increase of CD4 T-cell counts. 
jp542/ HAART: cost/benefit ratio in an Italian cohort 
of HIV patients 
R. Bruno', P. Sacchi', S.F.A. Patruno', E. Brunetti', P. Piacentini', 
F? Legnazzi', G. Filice'. 'Division .f Inzrfious and Tropical Diseases, 
'Department .f Pharmacology, IRCCS S. Maffeo, University of Pavia, 
Pavia, Italy 
Objectives: To evaluate HAART (highly active antiretroviral ther- 
apy) cost/benefit ratio in a cohort of HIV patients with less than 
200/mm' CD4 cell count. 
Methods: In 1996-97, 181 HIV patients with CD4 counts less 
than 2 0 0 / m '  were treated initially with double NRTI therapy and 
then with HAART. Blood cell count, kidney and liver function, HIV 
RNA and lymphocyte subpopulations were monitored. Number and 
length of admissions due to opportunistic infections, incidence of 
AIDS-defining events (ADEs), number of deaths and direct costs 
were evaluated. 
Results: During follow-up, hospitalizations decreased from 154 
to 118, while hospital stays dropped from 3429 to 2832 days, with a 
decrease beginning at the start of the second 4-month period of 
1997. There was a decrease in the incidence (70%) of ADEs com- 
pared to 1996. There was a constant decrease in deaths in 1997 
compared to 1996, when there was a peak in the third 4-month 
period. Total costs of our patient cohort were similar for 1996 and 
1997, with a shift occurring from hospitalization costs to antiretro- 
viral therapy costs. 
Conclusions: Our data indicate that patients with CD4 
<200/mm3, those involving the highest health costs, do not result in 
relevant added costs when HAART is used, since only a shift from 
one type of cost to another ensues. 
Discontinue and switch therapy with protease 
inhibitors in HIV-infected patients 
J.M. Guardiola, F. Madrid, F? Domingo, J. Ris, M .  Gurgui, M.A. 
Sambeat, M. Fuste, J. Barrio, G. Vazquez. Infernal Medicine, Hospital 
Sant Pau, Barceiona, Spain 
We studied the reasons for PI change and compared the antiretrovi- 
ral efficacy of two PI-based regimens: used as first choice (FC) and 
second choice (SC) after 18 months of follow-up. 
Patients and methods: 653 patients began HAART and only 69 
(10.5%) needed PI change. Average age was 36.827.4 years (range 
26-60). 38 were men (55.07%). Mean time since diagnosis of HIV 
was 6.2k3.04 years (range 1-13). Duration of prior antiretroviral 
therapy was 293222.38 months (range 1-84). Data related to PI as a 
jirst choice (FC): Treatment was maintained for 4.89k3.71 months 
(range 1-15). Basal CD4 was 173/mm3'175 and basal viral load was 
5.6825.19 log (M.82) .  Indinavir (IDV) had to be withdrawn in 26 
of 456 cases (5.7%), in 12% because of TF and in 88% due to SE. 
Saquinavir (SQV) had to be withdrawn in 16 of 130 cases (12.3%), 
75% because of TF and 25% due to SE. Ritonavir (RTV) had to be 
withdrawn in 27 of 67 (39.9%), 12% due to TF and 88% due to SE. 
Data related to second choice PI (SC): Treatment with PI until comple- 
tion of study was 14.1k3.2 months (range 8-20). CD4 count at 
beginning of SC was 270/mn~"36 and viral load was 5.27'4.75 log. 
SQV had to be withdrawn in 22 cases and RTV in 8. As FC and SC, 
the changes in viral load were -5.34 and -5.15, -5.85 and +5.10, and 
+5.19 and +4.45, with IDV, RTV and SQV respectively. CD4 
improvement (FC and SC) was: 111 and 103, 76 and 169, and 121 
and 30, with IDV, RTV and SQV respectively. 
Conclusions: FC: Those PI-based regimens including IDV had 
significantly lower percentages of therapeutic failure and treatment- 
limiting side effects. SC ; IDV has shown greater virologic improve- 
ment than RTV or SQV but without reaching statistically significant 
differences 
lp5441 Relationship between plasma HIV-1 RNA at the 
nadir and duration of viral suppression during 
antiviral triple therapy 
H. Knechten, B. Lippok, €? Braun. PZB, Aachen, Germany 
Objectives: To investigate the relationship between the initial 
decline of plasma HIV-I RNA and duration of viral suppression. 
Methods: Retrospective analysis of data of 35 naive (group A) and 
54 therapy-experienced (group B) patients treated with indinavir, 
lamivudin and zidovudin or stavudin in 1996/97. The viral load was 
determined with Amplicor HIV-1 Monitor (Roche), with a lower 
limit of quantifiability of 400 copies/mL HIV-1 RNA and a variable 
limit ofdetection lower than 400 copies/mL. To analyze values under 
400 copies/mL HIV-I we distinguish between BQL (below quan- 
tifiable limit, but detectable) and BDL (below detectable limits). 
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Conclusions: The viral load of patients which has not reached 
the lower limit of quantifiability of 400 copies/mL at week 12 will 
not decrease with ongoing therapy. The detection of low levels of 
HIV-1 R N A  in plasma (BQL) was not necessarily associated with a 
higher likelihood of future virologic rebound in the following 20 
weeks. To distinguish between BQL and BDL, tests with a lower 
limit of quantifiability of 50 copies/mL should be used, 
lp5451 Triple therapy with three nucleoside reverse 
transcriptase inhibitors: good control of HIV-1 
viral replication 
0. Bosco, G.C. Fibbia, M. Gomma, G. Serpelloni. Sezione di 
Screening HIK Verona, Italy 
Introduction: Before the introduction of protease inhibitors (PIS), 
in our center some patients showed an immunologic progression of 
HIV infection although they were taking two nucleoside reverse 
transcriptase inhibitors (NRTIs). We intensified the treatment of 
these patients by introducing a third NRTI. 
Objectives: (1) To evaluate CD4+ and CD8+ T-cell count trends 
in antiretroviral-treated patients with three NRTIs. (2) To evaluate 
viral load decrease with this therapeutic regimen. 
Methods: Seven patients (2 females, 5 males) were included in 
the three-NRTI treatment. Three subjects were treated with 
D4T+3TC+ddl and 4 with AZT+3TC+ddl. Patients' mean age 
was 41.8 years and mean duration of HIV infection was 7.1 years. 
Virologic and immunologic controls were performed at baseline, 
1 and 3 months and every 3 months thereafter. 
Results: The baseline values for T-lymphocytes were as follows: 
CD4 326/mL, CD8 862/mL CD4/CD8 ratio 0.41. After 18 months 
of treatment, the mean CD4 cell count was 536/mL (increase of 210 
cells/mL), and that of CD8 was 1169 cell/mL (increase of 307 
cells/inL), CD4/CD8 ratio 0.52. After 3 months of treatment, the 
viral load of 33.3% of patients was below the limit of quantification; 
these ratios increased over time (60% at 6 months and 70% at 12 
months) and, at the end offollow-up, only one subject had detectable 
viral load (452 copies/mL; cRT-PCR). 
Conclusions: The combination of three NRTIs in patients with 
HIV infection seems to be an effective regimen in controlling HIV 
replication and in achieving partial immune reconstitution. In addi- 
tion, this treatment is a reserve for the use of protease inhibitors in 
case of failure of this regimen. 
-1 A Phase 111, multicenter, randomized, 
openlabel study to compare the antiretroviral 
activity and tolerability of efavirenz (EFV)+ 
indinavir (IDV), versus EFVt  Zidovudine 
(ZDV)+lamivudine (3TC), versus IDV+ZDV+ 
3TC at 4% weeks (Study DMP 266006) 
macrolide subinhibitory concentrations 
S. Staszewski', K Tashima', R. Stryker3, P Johnson4, M. Nelsons5 
J. MoralesRamirez6, D.J. Manion', D. Farina', D. Labriola', N. 
Ruiz', and The Study 006 Investigator Team. 'Klinikum derJ W 
Goet/ieUriivc.rsitaet, Frankjurt, Germany; 2 T h e  Miriam Hospital, 
Providence, RI; 3Pac~fic. Oaks Research, Beverly Hills, CA; 'UT Health 
(Scienre Center, Houston, T X ;  'S t  Stevens Centre, London, UK; 'Doctor 
Diego Building, SanJuan,  PP; 'DuPurzt Pharniacenticals Company, 
Wilmington, DE 
Background: Efavirenz (SUSTIVATM) is a oncedaily NNRTI. 
Study Design: Randomized, openlabel study of PI, NNRTI, and 
3TCnaive patients, 86% male, 60% Caucasian; age, 36.3 (+8.2) years: 
85'%1 Txn2ive; HlVl RNA: 4.7720.57 10s 10 copiec/ml; CD4 
count., 345.31202.7 cells/mm3. 
Methods of analysis: observed data (OBS), intenttotreat: last 
observation carried forward (LOCF), and ITT: noncompleter= 
failure (NC=F). 
*Statistically significant EFV+ZDV+3TC over 11>4+ZDV+3TC 
(p<0.05). Similar trends seen patients with baseline HIV.RNA 
>=100,000 copies/mL. CD4 count increases ranged froiii 179201 
cells/mm3. EFVcontaining regimens were generally well tolerated 
with few newonset AEs after week 12. 
Conclusions: Compared to IDV+ZDV+3TC, EFVfZLIVf3TC 
offers superior effiicacy with durability of respome to at least 48 
weeks, better tolerability and getter convenience. EFV+ZIlV+3TC 
should be considered a superior first line therapy to the current 
Plcontaining standard of care for HIVinfected paticnts including 
those with baseline HIVRNA> =100,00O/mL. 
I P546 1 Ritonavir confers superior HIV-RNA 
suppression for PI-experienced patients in 
single and combination regimens compared to 
other PIS 
M.K.  Kawlings', S. Mayer', C. Holtzcr', J. Uarrett', C. de 
Guzman4, D. Lapins'. 'Parkland Health and Hospital S)atem, Dallas, 
T X ,  'Ahbott Laboratories, Abbott Park, IL, -'Sat1 Francisco Gpneral 
Hospital, San Franciscu, CA, 4Clinical Partrier.& Saw Francisc~l, CA, 
U S A  
Objectives: To analyze and compare the virologic cuccess of both 
single PI-experienced and PI conibinatiori-experienced paticnts in 
managed care 
Methods: Clinical Partners analyzed data on managed care 
patients (pts) during all 12 months of 1996 and 1997 (pts=916, 931; 
pt nionths=9244, 9680) and the first 5 months of 19% (ptq=776; pt 
months=4301). (A pt month (PM)=any month in which a p t  is on 
HAART.) The pt population was commercially insured, ncin- 
IVDUs, age 25-45; 95%) white males. CD4 count, viral load and 
HAART regimen were extracted from payor claims, PBM files, elec- 
tronic download of laboratory reports, and chart auditc. Supprestion 
was defined as 2 1 viral load <400 cop~edmL utilizing a PCK a w y  
Results: 
Conclusions: For pts with prior PI experience, the data suggest 
that RTV may be superior to IDV when used as a single PI. For PI- 
experienced pts utilizing PIS in combination, the RTVIIDV combi- 
nation showed higher levels of suppression when compared to 
combinations of RTV/SQV, SQV/NLF, NLF/IIIV, and SQV/Il2V. 
Additional data to follow. 
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(p5471 Efficacy of the ritonavir-saquinavir 
combination in naive and experienced HIV-1- 
infected patients 
N. Boffa', VD'Aiuto', C. Nacca2. Infectious Diseases, 'Salerno, 
'Caserfa, Italy 
Objectives: To evaluate the efficacy and safety of the ritonavir- 
saquinavir (RTV-SQV) combination in naive and experienced 
HIV-1 -infected patients. 
Methods: Between August 1997 and October 1998, we evalu- 
ated RTV (800 mg/day)-SQV (800 mg/day) in experienced and 
naive HIV-1-infected patients. Clinical events, HIV-1 viral load and 
CD4+ lymphocyte count were analyzed at 0, 3 and 6 months. 
Results: 23 patients (9 naive, 14 experienced) were enrolled in 
this study. Of these, 20 were men and 3 women; the mean age was 
37 years (range 25-54), and the mean duration of treatment with 
RTV-SQV was 3-6 months. Again, AIDS events were dagnosed in 
2 patients. In the 9 naive patients, the decrease in viral load was 
1.97  log,^, by the third month and 2.59 bglCJ by the sixth month, and 
the mean CD4 cell count increased from 150 by the third month to 
200/mm3 by the sixth month. In the 14 experienced patients, the 
decrease in viral load was 0.5 1og10, and the mean CD4+ cell count 
increased from 104 by the third month to 115/mm3 by the sixth 
month. 
Conclusions: Our experience confirms that in the naive patients, 
this combination is highly efficacious, and, in contrast, in severely 
immunodepressed HIV-1-multiexperienced patients, the eficacy is 
less. RTV-SQV was well tolerated. 
[p548[ The influence of intensive medication 
adherence strategies on the clinical outcome of 
HIV-infected patients taking protease inhibitors 
(Pis)-12-week interim analysis 
C. Holtzer, EM. Hecht, M. Swanson, P. Ruane, S. Schrader, C. de 
Guzman, D. Lapins, J. Stansell, San Francisco General Hospital, 
UCSF A I D S  Program, San Francisco, C A ,  USA 
Objectives: To explore the influence of an adherence intervention 
on the clinical outcome of PI therapy. 
Methods: Patients (pts) from three clinics were randomized to 
receive either a non-intervention Medication Event Monitoring 
System (MEMS) TrackCap with usual care or a MEMS SmartCap 
with adherence counseling and follow-up reports consisting of dosing 
alarms, daily dose-taking reminders, and at least bi-weekly follow-up 
phone calls based on dosing patterns provided by dosing partners. Pts 
utilizing a MEMS SmartCap downloaded their dosing patterns every 
day via modem to study personnel. Pts only utilized caps on PI 
bottles. Pts utilizing MEMS TrackCap returned caps to study person- 
nel every 12 weeks. 
Results: Pts included in the analysis (n=66) were male (97% 
usual care, 100% intervention). HIV risk categories: MSM (84%, 
91%), MSM/IVDU (1396, 6%), Het (3%, 3%). Baseline CD4 count: 
(1796, 18%). Undetectable baseline VL (<500 copies/mL) (71% 
91%). PI at baseline: SQV (696, 0%), IDV (38% 30%), RTV (13% 
12%), NLF (22%. 27%), SQV/RTV (23%, 30%). Median adherence 
for the usual care cohort was 91% and intervention was 96% 
(p=0.11). The log change in viral load from baseline (n=44) for the 
usual care cohort was +0.32 log, and that for the intervention was 
-0.55 log (p=0.09). Mean change in CD4 count from baseline 
(n=42): +84 cells/mL for usual care cohort, f 80  cells/mL for 
intervention cohort (p=0.93). 
0-100 (7%, 6%), 101-200 (24%, l5%), 201-500 (52%, 62%), 500 
Conclusions: In this ongoing, clinical trial, active intervention in 
PI adherence may improve clinical outcome in PI-based antiretrovi- 
ral therapy 
w] Early combination therapy with two 
nucleoside analogs: results of a retrospective 
study 
Y. Douadi, C. Kougougan, S. Redeker, A. Smail, J.-L. Schniit, 
CHU Snd, Patholofies infectieuses, Arniens, France 
Background: At the present time, the goal of antiretroviral therapy 
is to maintain the viral load helow the level of detection with mini- 
mal discomfort and toxicity for the patients In this setting combina- 
tion of a protease inhibitor (IP) with two nucleoside analogs (NA) is 
more potent but generates more side effects than bi-therapy without 
IF? 
Objectives: To ascertain retrospectively baseline characteristics of 
patients treated with two Nas in our institution. 
Methods: We compared baseline characteristics (CD4+ cell 
count, viral load) of patients with optimal response (viral load M6 
C2.7 logllJ copies/mL) (500 copies/mL) and suboptimal response 
(viral load M6 2.7 loglr, copies/mL) with NA. All patients treated for 
at least 6 months with 2 Nas, and whose viral load had been assessed 
before treatment, were distributed in two groups: group A=patients 
with optimal response; group B=patients with suboptimal response. 
Statistics: wilcoxon test, Fisher one-tail randomized exact test. 
Results: 22 patients were studied, and 4 were asymptomatic. 
There was no statistically significant difference between the follow- 
ing baseline values: CD4+ cell count, CD4/CD8 ratio, viral load. 
However, patients with optimal response were more likely to have 
baseline viral load equal to or less than 4 logm copies/mL (7 patients 
/11) than patients with suboptimal response (3/11) (p=0.015). 
Conclusions: Early treatment of HIV infection with a combina- 
tion of two nucleoside analogs can lead to satisfactory results in 
asymptomatic patients with less than 4 logto baseline viral load. 
Twice-daily versus daily indinavir (IDV) in 
combination with DDI and D4T AGUA Study 
D. Dalmau, A. Guelar, L. Gomez, H. Knobel, X. Martinez-Lacasa, 
J.L. Colomes, C. Sanchez, F? SabaUs, JJ. Herneki, J. Garau, Hospital 
Mutua de Terrassa, Ivfictious Diseases Unit, Zrrarsa, Spain 
Adherence is a major concern in antiretroviral (ART) therapy. There- 
fore, attempts to simplify dosing regimens must be emphasized. 
Objectives: To compare the efficacy, safety and adherence of 
twice-daily IDV (q 12H group: IDV 1200 mg every 12 h) to that of 
a thrice-daily IDV regimen (q 8H group: 800 nig every 8 h), 
combined with d4T (30/40 mg every 12 h) and DDI (300/400 mg 
every 24 h). 
Methods: Multicenter, open-label, prospective, randomized 
ongoing trial. Inclusion criteria: viral load (VL) higher than 5000 
copies/mL and protease inhibitors (PI), d4T and DDI non-experi- 
enced patients. 
Results: To date (October 1998). 64 patients have been included. 
Subjects were 66% male, with a mean age of 35 years. The majority 
of them (76%) were ART naive and 73% were asymptomatic. Mean 
baseline VL and CD4 data were 63 665 copies/niL and 31 1 cells/mL 
respectively, without differences between groups. In an intention-to- 
treat analysis, 10 (26%) patients in the q 12H group and 4 (16%) in 
the q 8H group discontinued study due to adverse events. Optimal 
adherence: 70% in the q 12H group versus 72% in the q 8H group. 
Undetectable VL (less than 80 copies/mL) at week 14 of follow-up 
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was achieved in 7S’% in reginien q 12h versus 17% in the q 8h regi- 
ineii (Fischer exact test: p=0.04; RR 4.595% Cl  0.7-28). The mean 
(SD) increase of CD4 cell count was 166 (217) cells/mL in the q 12h 
regimen and 91 (88) cells/niL in the q 8h regimen. 
Conclusions: Our preliminary data suggest that antiviral activity, 
adherence and safety profile of the twice-daily regimen are at least 
equal to those of the thrice-daily regimen. Updated efficacy and 
safety will be presented. 
1p5511 Utility of serum antiretroviral level monitoring 
and relationship to adherence and response to 
treatment: a pilot study 
2. Teniesgen, T. Moyer, R. Enger, L. Estes, J. Charlson, L. Oliver, 
A.  Wright, hLiyo Clinic, Infectious Diseases, Rochester, hlN, USA 
Objectives: This study was designed to validate the niethodology 
for measuring serum concentrations of antiretrovirals and to deter- 
mine if levels correlate with adherence and clinical outcome. Samples 
were obtained from HIV-Infected patients (pts) on highly active anti- 
retroviral therapy (HAART). Kesults from the first 6 evaluable 
patients are presented. 
Methods: Blood was drawnjust before dose (trough) or 2 h after 
the PI dose (peak). liidinavir (IND), nelfinavir (NFV), ritonavir 
(KTV) and saquinavir (SQV) were extracted using ethyl acetate and 
hexane and analyzed by HPLC on reverse phase with UV detection 
at 254 nni. Valuer were compared to reference ranges. Treatment 
responders were those with HIV R N A  below 400 copies/inm”. 
Adherence was estimated through patient interviews. 
Results: Four patients were on IND-containing regimens, 1 
received NFV, and 1 was on an SQV-based regimen. Five patients 
were on their initial regimen. O f  these, 4 were responders. 
mI Hypertriglyceridemia in patients with HIV 
disease: frequency and role of antiretroviral 
treatment 
R. Manfredi, M. Borderi, S.Talh, S. Spinosa, M.Tadolini, 
C. Donzelli, E Chiodo. D p r f m e n t  of Clinical and Experimental 
hfedirine, Universify qf Bologna, Italy 
Objective: To assess the frequency of hypertriglyceridemia (HT) 
during HIV disease, and its relationship with antiretroviral treatnient 
Methods: Forty patlents treated with ritonavir (RTV), 40 
receiving indinavir (IDV), 40 treated with reverse transcriptase 
inhibitors (KTIs) only, and 40 who did not receive (or refused) 
antiretrovirals, were randomly selected among -1000 HIV-infected 
patients followed by us, provided that they had four consecutive 
laboratory evaluations carried out every 3 months, while on the 
relevant medication, since 3 months of H T  was defined by plasma 
triglyceride levels of 172 mg/dL 
Results: Our four patient groups were comparable as to 
demographic features (data not shown), underlying immuno- 
deficiency (mean CIM+ lymphocyte count), and duration of therapy 
with either KTV, DV, or RTI. Fifty-one patients of 160 (31.9%) had 
at least one positive result for H T  during their follow-up, but sign- 
ficant differences were seen between patients treated with RTV or 
IDV, and those receiving RTI or no therapy, as to occurrence of H T  
(p<O.OOl, chi-square test), and mean and peak plasma triglyceride 
levels (p<O.OOl, Student t-test). Compared with the IDV group, the 
RTV group included a significantly greater number of patients 
developing H T  (p<O.OOl) ,  and showed much higher mean and peak 
plasma triglyceride values (p<O.001), with levels > 1500 mg/dL 
being reached in five patients after 6.2k1.8 months. No clinical 
disturbances attributable to H T  were seen, but in 12 patient5 anti- 
hpeinic agents were introduced, and six patients interrupted their 
treatment due to persistently elevated H T  
Conclusion: H T  is increasingly recognized among HIV-infected 
patients, but Its frequency and severity appear to be strictly related to 
anti-HIV therapy carried out with some protease inhibitors. Careful 
monitoring of plasina triglyceride levels is mandatory for patients 
treated with RTV 
(p552( The potential impact of efavirenz on 
methadone maintenance 
T. Bose, K. Tashima, J. Gormley, H. Sousa, T.P. Flanigan, The 
hfiriani Hospital, Providence, RI, U S A  
Objectives: To exaiiciie the relationship between antiretroviral 
medication and adjustments of methadone dosages in seven patients 
enrolled in the DMP 266-006 trial. 
Methods: Case report forms were reviewed for changes in metha- 
done doses among seven patients on chronic methadone maintenance 
enrolled in DMP 266-006. Patients were contacted by telephone to 
confirm these changes. 
Results: All five of the patients on the efavirenz-containing 
arnis (three on AZT/3TC/efavirenz; two on efavlrendindiiiavir) 
increased their methadone dosage after starting their study medica- 
tion. The mean methadone increase with those on an efavirenz- 
containing regimen was 22.2 mg (range 5-50 nig), The two patients 
who did not have efavirenz included in their regimens had either no 
change or a reduction in their methadone dose since starting the 
study. Four out of the five patients on an efavirenz-containing regi- 
men have had at least one herom relapse since starting the study. 
Neither of the two patients on AZT/3TC/indinavir had a heroin 
relapse. Pharmacokinetic data for efavirenz and methadone will be 
presented. 
Conclusions: This report is anecdotal becduse of the small 
number of patients, but it points out the critical need for further 
investigation into diffrrent antiretroviral agents and possible iiiterac- 
tions with methadone. Providers need to be aware of thew potential 
interactions. 
Ip5531 Use of recombinant human erythropoietin 
bHuEPO) for AIDS patients in the HAART era 
A. Mastroianni’, C. Cancellieri’, C. Baccini’, E Allegrini’, S. 
Pignatari’. ‘Division qf Infectioirx Diseases, ‘G. B. h fo ipqni ’ ,  Gmeml 
Hospital, Forlt, ‘Laboratory, ‘S. Maria  delk Croci’ General Hospital, 
Ratwna, Italy 
Objectives: To evaluate the efficacy and toxicity of treatment with 
rHuEpo support in AIDS patients (pts) with chronic anemia treated 
with multidrug regimens. 
Methods: Between November 1996 and June 1998, 15 (12 males, 
3 females) consecutive pts with chronic anemia were enrolled into 
this study Their median age was 34 years (range 28-54), According 
to the classification established by C D C  (1993), all pts had C3 stage 
disease. The evaluation of pts included a full blood count and retic- 
ulocyte count, liver and kidney function tests, seruni iron, ferritin, 
and transferrm. These tests were monitored weekly during the first 
2 months, and once a month thereafter. Serum endogenous EPO 
level was assayed at study entry with a coniiiiercially available 
radioimmunoassay. All pts were treated with rHuEP0 (alpha epoetin) 
100 U/kg given subcutaneously 3 tiines weekly for 8 weeks. 
Response was defined as an increase in hemoglobin value of 1 0  g/L 
after 4 weeks of therapy with rHuEPO without blood transfusion$. 
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Results: The mean EPO level was 62 mU/mL (range 8-267). 
There was evidence of a trend toward a positive response in a t  least 
80% of all treated pts. A mild skin reaction at the injection site 
occurred in 35% of pts. No other adverse experiences were 
observed in any patient. Transfusions were required only by 3 pts. 
A progressive improvement in quality of  life was noted in all 
responding pts. 
Conclusions: In spite of the several reports about the EPO effect 
in ZDV-associated anemia, there is little information for safety and 
efficacy of rHuEPO in the treatment of anemia in pts with concomi- 
tant HAART. The results of this survey suggest that rHuEPO appears 
a convenient alternative to blood transfusions, in an attempt to over- 
come chronic anemia as a possible side effect of multidrug antiviral 
regimens that are frequently used in pts with HIV disease. 
(P554f Suppression of viral load in the female genital 
tract and cerebrospinal fluid (CSF) in patients 
on combination therapy including efavirenz 
K. Tashima, S. Cu-Uvin, A. Caliendo, J. Gornlley, T. Flanagan 
Miriam Hospital, Providence, RI; Massachusetts General Hospital, 
Boston, MA, USA 
Objectives: Viral replication and latency in sanctuary sites may 
hinder efforts to eradicate HIV infection despite the best antiretrovi- 
ral combinations. 
Methods: Five female patients beginning an efavirenz-containing 
regimen underwent cervicovaginal lavage (CVL) and two of these 
women agreed to lumbar puncture. Viral loads were measured by 
NASBA for CVL and platma specimens and by Amplicor Monitor 
assay for CSF specimens. 
Results: In four of five women on treatment with efavirenz- 
containing regimens, the CVL viral load was <400 copies/mL at a 
mean of 22 weeks (range 2-52 weeks) on therapy. One woman with 
prior NRTI treatment had a persistent virus in CVL (3400 and 7000 
copies/mL) while on treatment with stavudine, indinavir and 
efavirenz, and she had subsequent virologic failure in plasma. In one 
woman who underwent lumbar puncture, the CSF viral load was 
<400 copies/mL at 6 months on treatment with an efavirenz- 
containing regimen. CSF data on another patient will be presented. 
Conclusions: These data demonstrate the ability of efavirenz- 
Containing regimens to suppress viral load in CSF and CVL in 
conjunction with suppression of HIV viral load in plasma. In one 
patient with resistant virus in plasma who did not respond to an 
efavirenz regimen, CVL viral load was persistently 400 copies/mL. 
Failures to suppress virus in CVL or plasma in these patients may be 
related to prior antiretroviral experience and/or advanced HIV infec- 
tion. 
lp5551 Presence of reverse transcriptase mutations in 
naive HIV-infected patients 
G. Martinez. C. Compelo, A. Merchin, I .  Madarieta, L. Sarria, R. 
Cisterna, Study Group of Antiretroviral Resistance. Department of 
fmmunoio~qy, Microbioiofiy and Parasito/ofl, sciiooi q/lbfedicine, Bifhao, 
Spain 
Objectives: The aim of this study was the evaluation of the pres- 
ence of natural mutations in antiretroviral-naive patients. 
Methods: Genomic DNA isolated from peripheral blood 
mononuclear cells (PBMCs) from 17 naive HIV-infected patients was 
subjected to nested PCR, using standard HIV-1 primers. Reverse 
transcriptase mutations corresponding to 41, 70, 215, 74, 75 and 184 
codons were detected by a hybridization microtiter assay using the 
samples that contained the corresponding mutations. Negative and 
positive controls were included. 
Results: Reverse transcriptase mutations were detected in 10 
patients (58.8%). All ofthem presented AZT mutations in 41, 70 and 
215 codons, alone as well as in combination. In this group the 75 
mutation (ddI/ddC, d4T) was observed in 5 patients (50%); one of 
them (20%) also had a mutation in the 74 codon (ddI/ddC). Only 2 
patients (20%) presented the 184 mutation (ddI/ddC, 3TC) and one 
of them was in combination with the 74 mutation. 
Conclusions: Our data show the importance of the appearance 
of natural mutations in HIV-infected patients. This presence seems 
to affect not only the corresponding AZT resistance codons but the 
codons related to other antiretroviral treatment such as ddI/ddC, d4T 
and 3TC. 
(p556] Comparative study of specific nested-PCR, 
hybridization microtiter assay and DEIA for the 
detection of AZT resistance mutations in HIV- 
infected patients 
G. Martinez, A. Merchin, L. Sarria, R. Cisterna, Study Group of 
Antiretroviral Resistance. Departmcnt of Zinmunology, Microbiolop~ and 
Paraxifohn, School oJMedirine, Biiiiao, Spain 
Objectives: To study the agreement of these three methods in the 
detection of AZT mutations. 
Methods: 42 peripheral blood mononuclear cells (PBMCs) from 
HIV patients were tested for AZT mutations (70, 215) by using 
nested-PCR with specific primers, hybridization microtiter assay 
(HMA) and DEIA (Sorin Biomedica). All the data were statistically 
treated applying the Pearson-chi square and Cohen’s Kappa. 
Results: The results are shown in the following table: 
Conclusions: The results obtained reveal that the agreement 
measure among the three techniques is higher for the 215 mutation, 
probably due to its frequent presence in HIV patients. Specific 
nested-PCR and HMA show the highest percentage of agreement 
for both mutations. This may suggest the need for applying more than 
one method for the detection of AZT mutations. 
m] Genotypic resistance in HIV-infected patients 
E. Terrero, M.A. Colnienero, R. de la Corre, J. Torres, EJ. 
Rodriguez-Pifiero, Ed. Perea, J.C. Paloinares, University of Sevilla, 
Faculty o f  Medicine, Mirrohiolopy, Seville, Spain 
Objectives: To determine the prevalence of genotypic resistance to 
nucleoside analogs (NA) in HIV-infected individuals in Seville, anti- 
retroviral naive and antiretroviral experienced. 
Patients and methods: Primary mutant genotypes were exam- 
ined in plasma HIV RNA collected from 23 antiretroviral-naive 
subjects during 1998. Furthermore, drug resistance mutations were 
analyzed in plasma collected from 1 1 antiretroviral-experienced 
patients who had received at least two Nas. The mutation assay for 
genotypic resistance was performed using a line probe assay for recog- 
nizing mutations conferring resistance to zidovudine (ZDV), didano- 
sine (ddI), zalcitabine (ddC), and lamivudine (3TC). 
Results: One or more niutations associated with primary resis- 
tance to Nas were seen in 7 antiretroviral-naive (30%) patients. In all 
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hut one case, they were associated with ZDV resistance. In contrast, 
5 (45%) of the antiretrovir'il-experienced subjects harbored drug- 
resistant mutant viruses. The codon 215 mutation was found in 3 
patients who had been exposed to ZDV, the codon 70 mutation in 
2 and the codon 41 mutation in I (all of them associated with ZDV 
resistance); the codon 184 niutation (associated with resistance to 
3TC) w3s detccted in 3 of the 4 patients treated with 3TC; and the 
codon 74 mutation was found in only 1 of the patients treated with 
ddI. 
Conclusions: The prevalence of drug-resistant HIV-1 genotypes 
was 30% in antiretroviral-naive patients, all of whom had ZDV-resis- 
tam niutants, lower than that of antiretroviral-experienced patients, 
45%. 
(p5581 Resistance mutations in HIV-infected children 
J.C. Palomarcs, E.J. Perea, E. Terrero, R. De La Corte, J. Aznar, 
Uriiiwsity cf S c i d o ,  F a r d f y  if Mrdicirrc, Micrubiolu~qy, Scville, Spairr 
Objectives: To determine if knowledge of genotypic resistance 
influences disease progression. 
Methods: Eleven perinatally infected children were followed 
during a 3-year period by analyzing their plasma KNA, CD4+ 
lymphocyte counts, genotypic retistance to nucleoside analogs and 
clinical state. Samples were taken at study entry and every 3 months 
thereafter. Vireinia levels were determined using the Amplicor HIV- 
1 Monitor te5t (Koche), and CD4' lymphocyte counts were 
measurcd by flow cytonietry The mutation assay for genotypic resis- 
tancc was performed ming the High Pure Viral R N A  klt and Titan 
System RT-PCR (Boehringer-Mannheini) for HIV R N A  prepara- 
tion a id  cDNA synthesis and P C R  respectively. For detection of 
mutations in the aniplified fragments the LlPA HIV-1 RT 
(Innogeiieticc) hybridization assay was used. 
Results: None of the children without previous treatnient showed 
any mutation conferring resistance to the antiretroviral drugs stud- 
ied. Among the 8 pretreated children, one had primary resistance and 
three developed recistance to zidovudine during treatment. The 
genotypic resistmce mutations were always detected before any other 
change in disease progression markers. After a new treatment was 
started in the patient who developed resistance, the viral load showed 
a mean decline of 0.6 logl,~. Those children on a HAAKT regimen 
did not develop any resistance during the study period. 
Conclusions: Resistance detection should accommodate treat- 
ment h r  the individualized patient before any other marker and will 
help to avoid new mutations. 
wl Genomic variability and antibiotic resistance 
of sequential Pseudomonas aeruginosa 
isolates from bronchiectasis patients without 
cystic fibrosis 
I. Puiana', L. Gallego', G. Martin', E Lopez', J. Canduela', 
K. Cisterm'? 'Uwivusidad dr/ Pals Vascu, 'Hospital de Santa M a r i n n ,  
'Hosvirul de Basiwfo, B d h ,  Spain 
Objectives: Most of the typing studies on  P.ieudomorins aeruqinosa 
colonization and persistence in chronic lung diseases has been cen- 
tered on cystic fibrosis (CF) patients. However, this bacteriuin also 
causes important infections in bronchiectas~r patients without CF and 
it is bcneficial to ascertain if it is the same or a different strain which 
reappears in the sputum after some time and/or antibiotic treatnient 
Methods: Thirty-seven sequential isolates from eight non-CF 
bronchiectasis patients were selected for between 1 and 3 years and 
charxterizcd by two different PCR assays. Antibiotic susceptibility 
tests to aztreonam, aniikacin, ceftazidinie, ciprofloxacin, chlor- 
aniphenicol, cefotaxitne, cefuroximc, imtpeneni, nieropeneiii and 
ofloxacin were done 
Results: All patients had several hospital stays (range 7-49). I t  is 
of interest that four patients were found to harbor a mix of mucoid 
and non-niucoid isolates. Eleven diffkrent genotypic patterns were 
observed among isolates. Three of the eight patient\ were infected by 
two different strains, while five were each infected by the same strsin. 
All the isolates, except one, were susceptible to carbapencnis. Nine 
of 11 clones developed resistance to aztreonain and six to cipro- 
floxacin and ofloxacin. In all cases the last isolate of each patient 
showed the higher resistance level 
Conclusions: I? aerqinusa infections in the patients studied were 
pi-oduced by a single clone or a maximum of two clones. Although 
there was phenotypic heterogeneity among the sequential isolates 
(i~iucoidity, different antibiotic rcsistance profiles), the genotypic 
pattern was the same. This suggests that the persistence of I? urrr(yino.m 
in chronic lung infections of bronchiectasii patients involves different 
phenotypic alterations that enhance its capacity ti) survive i n  this 
environment 
w] Activation of immunocytes by an 
oligodeoxynucleotide homologous to the DNA 
of an acutely pathogenic SIV variant 
M.S. Lapatschek, H .  Wagner, T. Micthke, Inst. j h  .VJedirn/ 
Mirrubiulqy, Technolo~y Uniwrsify, Munidr, C~rrnariy 
Objectives: We asked if the acutely pathogcnic SIV variant 
SIVsiiiinpbj14, which causes niacrophage-dependent lymphocyte 
pi-oliferation in vitro, possesses DNA sequences which can directly 
activate macrophages. 
Methods: Cultivated macrophages or spleen cells were incubated 
with different SIV- and HIV-homologous oligodeoxyriucleotides. 
The activation status of the macrophages was determined by NF-LB 
translocation via EMSA, by TNF-RNA synthesis via Northern blot 
and by cytokine secretion via ELISA. Additionally, fluorescence of 
niacrophages transfected with an HIV-LTK luciferasc reporter 
construct was measured upon oligodeoxynucleotide stimulation. 
Treated spleen cells were analyzed for cytokine secretion via ELISA, 
for proliferation via ['Hlthyniidine incorporation and for cell type by 
flow cytonietry. 
Results: We found a DNA sequence in the ri<;f gene of 
SIVsininpbjl4 which activates macrophages to a significantly higher 
degree than the respective DNA cequence of SIViiiac239, a non- 
acutely pathogenic virus. The iilirnunostlniulatory activlty of the 
sequence depends on the central CG motif as well ai on the flank- 
ing sequences. The DNA sequence induce.; the HIV-LTR promoter 
via activation of the host cell. DNA-stimulated spleen cells show U- 
lymphocyte proliferation. Siniilar DNA sequences found 111 other 
SIV and HIV strains, also \how immuno~tin~ulatory activity. 
Conclusions: We were able to show that SIVsininpbj 14 possesses 
at least one iiiiiiiunostiniulatory DNA cequence which could account 
for the induction of lymphocyte proliferation by the virus, possibly 
via cytokmec secreted by the activated macrophages. Given the fact 
that similar sequences in other HIV/SIV strains also activate 
immunocytes, one could hypothetize about a general phenomenon 
occurring during HIV pathogenesis, perhaps contributing to the 
TNF-mediated apoptosis of uninfectcd bystander cells or enhancing 
HIV proliferation via the LTK in a kind of autocrine loop. 
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[p5601 Quantitation of HIV-1 RNA: linking TMA 
amplification with the VIDAS Instrument 
J. L. Burg’, P.M. MacLean’, L. Catanzariti’, B. Weinbaum’, J.M. 
McCarty’. ‘bioMerieux, Inc., Rockland, M A ,  ’Gen-Probe, Inc., San 
Diego, CA, USA 
Objectives: To develop a test for HIV-1 viral load monitoring utiliz- 
ing Gen-Probe’s Transcription Mediated Amplification (TMA) tech- 
nology and automated detection on bioMerieux’s VIDAS system. 
Methods: HIV-1-positive plasma samples and HIV-1 viral cali- 
brators were prepared by target capture of HIV-1 R N A  onto para- 
magnetic particles. The particles were washed to remove potential 
inhibitors of TMA. Internal control (IC) R N A  was added and TMA 
was initiated at 42°C for 60 min. The resulting amplicons were trans- 
ferred to a VIDAS probe strip for automated detection (-2.5 h). The 
VIDAS detection protocol consisted of three segments; each used 
solid-phase capture and alkaline phosphatase-labeled reporter probes. 
The first and second segments detected diluted and undiluted HIV- 
1 amplicons, respectively, to achieve a broad dynamic range. The 
third segment detected IC amplicons to verify proper system perfor- 
mance for undetectable samples. Quantitation was achieved by inter- 
polation to the two calibration curves and is based on fluorescence 
kinetics. 
Results: The dynamic range of the VIDAS Probe Quantitative 
HIV-1 assay was 50-500 000 RNA copies/mL. Spiking negative, 
defibrinated plasma with HIV-1 virus showed positivity rates of 56%, 
92% and 100% for samples with 10, 25 and 2100 R N A  copies/mL, 
respectively. CVs ranged from 12% to 27% for samples 21000 R N A  
copies/mL. A comparison of this system with blinded patient 
samples, previously quantified by the Roche AMPLICOR HIV-I 
method, showed 86.1% concordance (difference <0.5 loglo), a mean 
difference of only 0.065 loglo RNA copies/mL, and excellent agree- 
ment (slope of comparative scatter plot was 1.021). 
Conclusions: The VIDAS Probe Quantitative HIV-1 assay has 
excellent sensitivity, precision, accuracy and dynamic range, and 
compares well with the Roche PCR-based test. 
Ip5611 Increase of HIV-1 viral load after hepatitis B 
immunization in seropositive patients 
S.H. Tuboi, V. Sinkoc, EH. Aoki, M.L.M. Branchini, P. 
Papaiordanou. Infectious Diseases Division, Universidade de Campinas, 
UNICAMI:  Brazil 
The increase in the HIV-1 viral load level in the peripheral blood of 
seropositive patients has been reportedly associated with influenza 
vaccination. This rise seems to be transient and occurs after 1 or 2 
weeks of vaccination. One potential mechanism of virus induction is 
immune activation, as some reports of studies in vitro have suggested. 
Other in vivo studies have shown that HIV-1-infected chimpanzees 
treated with various vaccine preparations had transient increases in 
infected peripheral blood mononuclear cells. 
Methods and results: HIV-1 patients were enrolled in a study of 
the immunogenicity of the hepatitis B recombinant vaccine. The 
viral load was measured about 4 weeks after the first dose of vaccine. 
We established 4 cases of an increase in HIV-1 R N A  levels after the 
hepatitis B vaccination. There were no symptoms of acute infections 
or allergies during the period following the vaccination. The mean 
CD4 count was 608/mm3 (range 291-874/mm3). Three patients 
showed increases in HIV-1 RNA levels higher than threefold and one 
showed a twofold increase. Three patients were under antiretroviral 
therapy. 
Conclusions: Like the influenza vaccine, the hepatitis B vaccine 
may lead to a transient increase of HIV expression. The response may 
be related to the different stages of disease and tends to be more vigor- 
ous at the early stage of infection. 
Lp5621 New HIV-1 gagDlenvG recombinant found in 
Russia 
E. Kazennoval, L. Selimoval, V Pokrovsky’, N. Ladnaya’, B. 
Foley”, J. Weber4, A. Bobkov’. ’D.I. lvanovsky Institute o f  Virology, 
’Federal AIDS Center, Moscow, Russia; ’Los Aiamos National 
Laboratory, Los Alamos, NM, USA; ‘Imperial College Scliool o f  
Medicine, London, UK 
Objectives: To characterize new gqD/cnvC recombinants found in 
Russia. 
Methods: PBMCs were taken from two males (RU1153 and 
RUll72)  infected with HIV-I. Both of them lived in Moscow but 
epidemiologic investigation did not reveal any link between these two 
cases. Amplified env (gp120) and gag (pt7/p24) gene fragments were 
sequenced. 
Results: The env gene sequences derived from RU1153 and 
R U l l 7 2  clustered with other members of env genetic subtype G but 
were significantly distant (17.8% divergent). Genetic distance in the 
env region between RUI153 and R u t 1 7 2  and other Russian env 
subtype G sequences, RU1120 and RU103a, was 11.3% and 21.5%, 
and 15.3% and 18.1%, respectively. On the other hand, the gag gene 
sequences derived from RU1153 and RU1172 clustered sigmficantly 
within the subtype D branch. Genetic distance between RU1153 and 
RU1172 in the gag region was low (4.8% divergent). 
Conclusions: These data allow us to suggest that RU1153 and 
RUI172 are infected with a new HIV-1 gagD/envG recombinant. 
lp5631 Serotyping of an HlVl-positive population 
C. Marques, E Ladeira, M.J. Silvestre. Microbiology Laboratory, 
Clinical Parholofy Department, Hospital de Curry Cabral, Lisbon, 
Portugal 
Objectives: To classify into serotypes A-E the patients of a popula- 
tion with positive serology for human immunodeficiency virus infec- 
tion type 1 (HIVl) and to correlate the obtained results with race, 
sex, risk group and response to antiretroviral therapeutics. 
Materials and methods: We studied 492 HIV1-positive indi- 
viduals (138 female and 354 male). AU ofthem were tested with the 
‘HIVl Subtype A to E Serotyping Kit’ (Boehringer Mannheim Lab. 
Diagnostics) and performed in an ES700 system. 
Results and conclusions: In all of the studied population we 
detected a predominance ofsubtype B (60.6%), followed by subtypes 
C (25.4%), A (3.9%), D (1.4%) and E (0.8%), besides the existence 
of mixed subtypes (6.5%) in certain patients and others that were not 
possible to classify (1.4%). In Caucasians subtype B is predominant 
(63.4%), while in black patients we detected a high percentage of 
subtypes C (50%) and A (28.1%). According to sex and risk group, 
we detected that the distribution of subtypes is similar to that in the 
population in general. Analyzing the response to antiretroviral 
therapeutics, we found that all the resistant patients belonged to 
subtype B. 
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(p564( Seroprevalence of HTLV-1/11 infection among 
females in prison 
f! Alvarez', M. Guti&rrez', E. Alvaro', A. Machuca', C. Toro', V 
Soriano', M. Baquero'. 'Hospital Carlos IIZ, 'Carabancltel Mujeres, 
Mududrid, Spairr 
Objectives: To study the seroprevalence of HTLV-1/11 infection 
among females in a prison of Madrid, Spain. 
Methods: 135 patients were tested to detect HTLV-1/11 infection. 
Questions on demographics, hexual behavior and drug use practices 
were asked. The diagnosis of HTLV-1/11 was made by the detection 
of antibodies using EIA (MUKEX HTLV-1/11, UK). Western blot 
(HTLV-1/11 W B  2.4, Genelabs, Singapore) was used as a confirma- 
tory test in double seroreactivity samples on screening test. 
Polymerase chain reaction (Aiiiplicor PCR HTLV-1/11) was used to 
coiifimi indeterminate pattern? in Western blot. 
Results: Of 135 patients, 69 (43.7%) were European, 10 (7.4%) 
Africans and 56 (41.48%) South Americans. We found 44 (32.6%) 
intravenous drug users (IDUs), 9 (6.6%) prostitutes and 21 (lS.S%) 
who had both risk factors. All IDUs were from European countries. 
Nine (6.6%) were infected by HTLV-11, all of them 1I)Us. A woinan 
born in Colombia (endemic area for HTLV-I) was infected by 
HTLV4 (0.796). She was neither an IDU nor a prostitute. 
Conclusions: We found two different epidemiologic groups 
living together in prison: females from South America and Africa 
(where HTLV-I is endemic) and IDUs (the main transmission route 
of HTLV-11) from European countries. Seroprevalence of HTLV-I1 
amoiig IDU females in prison (12%) does not show difirrences from 
data from IDU males imprisoned in Spain (10%). We thought that 
the high percentage of females from endemic areas in our study could 
explain the case of HTLV-I infection found. 
lp565) Sensitivity of immunocomplex-dissociated 
HIVp24 antigenemia compared with plasma 
HIV-RNA levels, evaluated on 2831 paired 
assays 
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Objectives: To compare iniiiiunoconiplex-dissociated HIVp24 aiiti- 
genemi3 and HIV-RNA levels as markers of viral replication. 
Methods and results: 993 consecutive HIV-infected patients 
underwent 2831 paired determinations of alkaline inimunoconiplex- 
dissociated HIVp24 antigenemia (immunoenzymatic assay, Organon 
Teknika), and HIV-RNA levels (by Quantiplex Chiron, Nuclisen 
Organon Teknika, or Amplicor Monitor Roche), in a 2-year period. 
Laboratory results were stratified according to HIVp24 antigenenna 
and HIV-RNA levels (Table). 
Discussion: When excluding patients with undetectable HlV- 
KNA levels (testing negative or borderline positive at p24 antigen 
assay in 97.9% of cases), ininiiinoconiplex-dissociated p24 antigene- 
inia proves significantly less sensitive than viral load at all considered 
HIV-KNA reference levels, although the inean value of positive p24 
assay5 parallels the trend of viral load. In particular, only 12.6% of 
patients with HIV-RNA levels ranging from 102 to lo4 copies/mL 
(needing immediate start of antiretroviral therapy according to 
present guidelines) have a positive p24 antigenemia, and even 34.4% 
of patients with a viral load of lo5 copies/niL (prompting initiation 
or change of highly active antiretroviral treatment) show a negative 
or borderline p24 antigenemia. In conclusion, immunocomplex- 
dissociated p24 .antigenemia has significantly lower sensitivity levels 
than HIV viral load, and cannot be any longer suggerted as a reliable 
diagnostic tool in the therapeutic management of HIV disease. 
lp5661 Nutrition as complementary therapy in AIDS 
patients 
L. Terra, K. Calzone, S. Pellican6, D. Mandica. Department .f 
Infctioltr Diseases, S. Giouan~ti di  Dio Hospital, Crotone, I fa ly  
Objectives: To elaborate a program to improve the nutritional status 
in AIDS patients (pts). 
Methods: 29 pts, 14 male and 15 female, referred to our depart- 
ment between January 1995 and August 1997, at ages ranging from 
38 to 47 years. were enrolled. Age, sex, height, weight, the body 
compartnients, total water, lean and fat mass, and dietetic daily ~ntake 
were evaluated every 15 days. Dietetic study included nutritional 
assessment, dietetic counseling, weight gain, group session, and 
follow-up. All had a nutritional supplement (500-1000 cal/day) for 
6-18 months (mean 15). Our dietists emphasize better food choices 
of pts 111 order to meet their individual needs like weight loss, drug 
interactions, nausea, diarrhea, and nutrimt deficiencies. 
Results: 19 pts (65%) showed gain weight (mean +5.8 kg); 8 pts 
(28%) had constant weight; 2 pts (7%) showed weight loss (mean - 
3.3 kg). 
Conclusions: Our study shows weight gain to be related to 
adequate dietetic treatment. Further trials are needed to evaluate 
whether systematic application of nutritional support can contribute 
to increased survival in these patients. 
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S. Pellican6, K. Calzone, D. Mandica, L. Terra. Dcyarfnient of 
lnjktions Diseases, S. Giovanni di Dio Hospital, Crotorie, I ta ly  
Objectives: To evaluate nutritional measures before and After 
protease inhibitor (PI) treatment. 
Methods: Between April 1995 and June 1998, 48 pts (42 male, 6 
female) with ages ranging from 30 to 68 years were enrolled for 2 
years in a study directed a t  the improvement of thcir nutritional 
status. 23 pts (48%), 17 male and 6 female (group A), started therapy 
with indiiiavir (57%) or ritonavir (43%)). Age, height, weight, the 
body compartments, total water lean and fat mass and dietetic daily 
iiitdke were evaluated every 15 days and medical treatment in group 
A was independent of the nutritional program 
Results: In group A, viral load decreased significantly (mean - 
1.2 log1o) in 21 pts (91%) and CD4 increased (mean -C78/nim3) in 
18 pts (78%)). In 19 pts (83%)) both weight and body fat increased 
with reduction of viral load o r  CD4 increase (piO.001; piO.0001). 
Conclusions: In our study, PI therapy improved nutritional status 
with an increase in body cell mass and body fat. We emphasize that 
indirect treatment effects, such as increased physical activity, may be 
implicated. Further trials are needed to confirm our data. 
